Find a Tender
active
Official procurement procedure
Aseptically Prepared Systemic Anti-Cancer Therapy Medicines
Pharmaceutical products
Published value
£850,000,000
Submission deadline 11 May 2026, 15:00 BST
Lots published4
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: MID AND SOUTH ESSEX NHS FOUNDATION TRUST: "Aseptically Prepared Systemic Anti-Cancer Therapy Medicines". Published status: active. Published value: £850,000,000. 4 published lots. Recorded submission deadline: 11 May 2026, 15:00 BST. See the official notice for participation instructions.
| Contracting Authority | MID AND SOUTH ESSEX NHS FOUNDATION TRUST | Scope & Categories | Not published | Submission Window | Closed 11 May 2026, 15:00 BST |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | £850,000,000 |
Bidder Intelligence · Authority Profile: MID AND SOUTH ESSEX NHS FOUNDATION TRUST
Market Analytics
Derived from OCDS awards & bid statistics
Published history for MID AND SOUTH ESSEX NHS FOUNDATION TRUST. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
3.2Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 24 active published awards; 6 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityMID AND SOUTH ESSEX NHS FOUNDATION TRUST | Procedure methodNot published | Procurement categoryNot published |
Statusactive | Framework / DPSFramework | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published13 Apr 2026, 10:48 BST | Last source update13 Apr 2026, 10:48 BST | Recurring procurementNot published |
ClassificationPharmaceutical products | ||
OCIDocds-h6vhtk-051cde | ||
What is being bought
This framework agreement is for the supply of a range of aseptically prepared, batch manufactured systemic anti-cancer therapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific systemic anti-cancer therapy drugs, CIVAs, and provisions for stock inventory management and supply of compounded systemic anti-cancer therapy.
What changed
From the official release history
- Published value updated to £850,000,000
13 Apr 2026, 10:48 BST - Status changed to active
13 Apr 2026, 10:48 BST - Official notice release published
13 Apr 2026, 10:48 BST - Submission deadline changed to 11 May 2026, 15:00 BST
13 Apr 2026, 10:48 BST - Published value updated to £700,000,000
12 Aug 2025, 13:02 BST - Official notice release published
12 Aug 2025, 13:02 BST - Status changed to planned
22 May 2025, 10:24 BST - Official notice release published
22 May 2025, 10:24 BST - Buyer information updated
22 May 2025, 10:24 BST
Lots and requirements (4)
Published by the contracting authority
- Lot 1 · #1Dose Banded Systemic Anti-Cancer Therapy MedicinesactivePublished value£850,000,000This Lot will cover the requirements for dose banded aseptically prepared systemic anti-cancer therapy medicines for adult and paediatric patients that can be supplied in batch or single units, and in line with National Dose Banded Tables where a specification exists.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 2 · #2Patient Specific Systemic Anti-Cancer Therapy MedicinesactivePublished value£850,000,000This Lot will cover the requirements for Patient Specific aseptically prepared anti-cancer therapy medicines in adult and paediatric patients.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 3 · #3CIVAS (Central Intravenous Additive Service)activePublished value£850,000,000This Lot covers the requirements for medicines used in CIVAs, and includes any preparation of medicine which is manipulated aseptically to create ready-to-use injectable medicine.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 4 · #4Stock Inventory Management and Supply of Compounded Systemic Anti-Cancer Therapy MedicinesactivePublished value£850,000,000This Lot covers the requirement for storage, warehousing, stock inventory management and stocking a range of batch systemic anti-cancer therapy medicines readily available for next-day or named day delivery.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
13 Apr 2026, 10:48 BST - Submission deadline
11 May 2026, 15:00 BST
Commercial outcome and competition
AwardsNo award published |
ContractsNo contract published |
Bid statisticsNo aggregate bid statistics published |
Buyer and organisations in this procedure
MID AND SOUTH ESSEX NHS FOUNDATION TRUST
Contracting authority GB-NHS-RAJDocuments (2)
Official links; attachments are not copied
- 13 Apr 2026, 10:48 BST
Related procedures (0)
No related procedures published